Pharmaceutical

Cancer biotech Inhibrx files for USD 75 M IPO Celgene-partnered biotech Inhibrx aftersecuring USD 40 Million from Viking Global Investors, has filed for USD 75 million IPO. Built on a single-domain antibody platform, it has three oncology programs in human clinical trials, a rare disease program, and two preclinical drugs. Inhibrx, has also granted Italian-based Chiesi Farmaceutici, the rights for the development and commercialization of AAT-fusion protein INBRX-101, outside of North America. Chiesi will pay USD 10 million upfront and buy a USD 10 million worth of shares in Inhibrx. EpimAb Biotherapeutics raises USD 74 M to accelerate bispecific pipeline Epi...